DK1231908T3 - Farmaceutisk præparat, der omfatter en NO-donorforbindelse samt anvendelse heraf - Google Patents

Farmaceutisk præparat, der omfatter en NO-donorforbindelse samt anvendelse heraf

Info

Publication number
DK1231908T3
DK1231908T3 DK00951577T DK00951577T DK1231908T3 DK 1231908 T3 DK1231908 T3 DK 1231908T3 DK 00951577 T DK00951577 T DK 00951577T DK 00951577 T DK00951577 T DK 00951577T DK 1231908 T3 DK1231908 T3 DK 1231908T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
donor compound
patient
isoform
protein
Prior art date
Application number
DK00951577T
Other languages
English (en)
Inventor
Maurice Israel
La Porte Sabine De
Philippe Fossier
Emmanuel Chaubourt
Gerard Baux
Christiane Leprince
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of DK1231908T3 publication Critical patent/DK1231908T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00951577T 1999-06-11 2000-06-09 Farmaceutisk præparat, der omfatter en NO-donorforbindelse samt anvendelse heraf DK1231908T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9907442A FR2794647A1 (fr) 1999-06-11 1999-06-11 Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules
PCT/FR2000/001612 WO2000076451A2 (fr) 1999-06-11 2000-06-09 Composition pharmaceutique comprenant du no un compose donneur de no, ou inducteur de la formation de no et son utilisation en therapie

Publications (1)

Publication Number Publication Date
DK1231908T3 true DK1231908T3 (da) 2004-06-14

Family

ID=9546698

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00951577T DK1231908T3 (da) 1999-06-11 2000-06-09 Farmaceutisk præparat, der omfatter en NO-donorforbindelse samt anvendelse heraf

Country Status (12)

Country Link
US (1) US6872751B2 (da)
EP (1) EP1231908B1 (da)
JP (1) JP2003506320A (da)
AT (1) ATE259223T1 (da)
AU (1) AU776692B2 (da)
CA (1) CA2376302A1 (da)
DE (1) DE60008293T2 (da)
DK (1) DK1231908T3 (da)
ES (1) ES2213032T3 (da)
FR (1) FR2794647A1 (da)
PT (1) PT1231908E (da)
WO (1) WO2000076451A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2847817B1 (fr) * 2002-11-28 2006-11-10 Centre Nat Rech Scient Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires
EP1596854A4 (en) * 2003-02-14 2007-06-06 Childrens Hosp & Res Ct Oak TREATMENT OF DISEASES RELATED TO REDUCED STICK OXIDE BIOVERABILITY, INCLUDING INCREASED ARGINASE
WO2005107384A2 (en) * 2004-03-31 2005-11-17 Nitromed, Inc. Methods for treating blood disorders with nitric oxide donor compounds
JPWO2007020917A1 (ja) * 2005-08-18 2009-02-26 国立大学法人徳島大学 ユートロフィン産生の増強持続剤とこれを用いる加工食品
DK1978947T3 (da) * 2006-02-03 2014-11-03 Nicox Science Ireland Nitrooxyderivater til anvendelse ved behandling af muskeldystrofier
US9452117B2 (en) * 2011-06-01 2016-09-27 The Charlotte-Mecklenburg Hospital Authority Nitrate esters and their use for the treatment of muscle and muscle related diseases
EP2837390A1 (en) * 2013-08-15 2015-02-18 Universitäts-Kinderspital beider Basel Combined Pharmaceutical Preparation for Use in Treating Neuromuscular Disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09508097A (ja) * 1993-11-02 1997-08-19 アメリカ合衆国 虚血再灌流傷害における保護剤としての酸化窒素放出化合物の使用
WO1995028377A1 (en) * 1994-04-18 1995-10-26 Abbott Laboratories Guanidine compounds as regulators of nitric oxide synthase
US5583101A (en) * 1994-07-15 1996-12-10 Harvard College Use of nitrogen oxide species and adducts to inhibit skeletal muscle contraction
US6153186A (en) * 1995-09-15 2000-11-28 Duke University Medical Center Red blood cells loaded with S-nitrosothiol and uses therefor
US6197745B1 (en) * 1995-09-15 2001-03-06 Duke University Methods for producing nitrosated hemoglobins and therapeutic uses therefor
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
WO1997033173A1 (en) * 1996-03-08 1997-09-12 The Regents Of The University Of California Muscular dystrophy, stroke, and neurodegenerative disease diagnosis and treatment
ATE331505T1 (de) * 1996-04-05 2006-07-15 Gen Hospital Corp Behandlung einer hämoglobinstörung
DE29709820U1 (de) * 1996-06-10 1997-07-31 NUTREND, s.r.o., Olomouc Lebensmittel-Spezialzusatz
CA2266908C (en) * 1996-09-27 2010-07-20 Joseph E. Saavedra O2-arylated or o2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and o2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates
US6110930A (en) * 1997-04-10 2000-08-29 Ono Pharmaceutical Co., Ltd. Condensed piperidine compound
AU726861B2 (en) * 1997-07-03 2000-11-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Novel nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same
CA2371927A1 (en) * 1999-03-11 2000-09-14 The University Of Manitoba Nitric oxide manipulation of muscle satellite cell activation
US6472390B1 (en) * 2001-11-13 2002-10-29 Duke University Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure

Also Published As

Publication number Publication date
WO2000076451A2 (fr) 2000-12-21
US6872751B2 (en) 2005-03-29
ATE259223T1 (de) 2004-02-15
EP1231908A2 (fr) 2002-08-21
DE60008293T2 (de) 2005-01-13
DE60008293D1 (de) 2004-03-18
AU776692B2 (en) 2004-09-16
WO2000076451A3 (fr) 2002-06-20
US20020164383A1 (en) 2002-11-07
PT1231908E (pt) 2004-06-30
JP2003506320A (ja) 2003-02-18
ES2213032T3 (es) 2004-08-16
AU6447300A (en) 2001-01-02
EP1231908B1 (fr) 2004-02-11
CA2376302A1 (fr) 2000-12-21
FR2794647A1 (fr) 2000-12-15

Similar Documents

Publication Publication Date Title
ATE322283T1 (de) Transdermale verwendung von sekretin zur behandlung von autismus
MY119231A (en) Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
ATE22535T1 (de) Pharmazeutische zusammensetzungen fuer die kontinuierliche freigabe des wirkstoffes.
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
IS1565B (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
BR9811093A (pt) Piridinas substituìdas com 2-amino-6-(4-fenóxi 2-substituìdo)
EP0147146A3 (en) Enhancement of transdermal drug delivery
DE69033970D1 (de) Huperzin a analoge verbindungen
HUP0100539A2 (hu) D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására
DE69812100D1 (de) Adenosin enthaltendes arzneimittel
DK0737069T3 (da) Deuterede aktive stoffer til transdermal administrering
PT1231908E (pt) Composicao farmaceutica compreendendo um composto dador de no e sua utilizacao em terapia
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
BR0112131A (pt) Composições farmacêuticas e métodos para uso
DE60108130D1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
HUP9901659A2 (hu) Flupirtin alkalmazása a hematopoetikus sejtrendszer károsodásával kapcsolatos megbetegedések megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására
ATE228843T1 (de) Verwendung von desoxypeganin zur behandlung von drogenabhängigkeit
BRPI0409790A (pt) 7-azaindóis e seu uso como terapêuticos
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen
DE3380923D1 (de) Pharmazeutische zusammensetzungen zur behandlung von stoerungen, bedingt durch humanendrogen.
BRPI0508053A (pt) método de combater toxicidade causada por um composto antifolato, e de tratar uma doença, usos de enzima que possui atividade de carbóxi-peptidase g, de composto antifolato, de agente de resgate de rota de folato, e de enzima que possui atividade de carbóxi-peptidase g e de um agente de resgate de rota de folato, sistema terapêutico, e, método ex vivo de clivar um grupo l-glutamato terminal de um composto, de determinar a taxa e/ou extenção de clivagem de um composto, e de clivagem de um composto
DE69428797D1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
UA23763A (uk) Спосіб одержаhhя лікувальhого засобу при захворюваhhях, що супроводжуються порушеhhям фуhкцій цеhтральhої hервової системи